Expanding the role of injectable collagenase clostridium histolyticum for the treatment of active phase Peyronie's disease

Affiliations

Comment

Louis A Aliperti et al. Transl Androl Urol. 2017 Feb.

. 2017 Feb;6(1):114-115.

doi: 10.21037/tau.2016.12.09.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
Yang KK, Bennett N. Yang KK, et al. Urology. 2016 Aug;94:143-7. doi: 10.1016/j.urology.2016.04.049. Epub 2016 May 17. Urology. 2016. PMID: 27211926

1. Yang KK, Bennett N. Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms. Urology 2016;94:143-7. 10.1016/j.urology.2016.04.049 - DOI - PubMed
1. Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207. 10.1016/j.juro.2013.01.087 - DOI - PubMed
1. Ziegelmann MJ, Viers BR, McAlvany KL, et al. Restoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolyticum Injection for Peyronie's Disease. J Urol 2016;195:1051-6. 10.1016/j.juro.2015.10.065 - DOI - PubMed
1. Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's Disease: AUA Guideline. J Urol 2015;194:745-53. 10.1016/j.juro.2015.05.098 - DOI - PMC - PubMed
1. Hellstrom WJ, Feldman R, Rosen RC, et al. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire. J Urol 2013;190:627-34. 10.1016/j.juro.2013.01.090 - DOI - PubMed